Citadel Advisors
SVA

Citadel Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

Citadel Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,000
Closed -$115K – 10370
2018
Q3 		$115K Sell
15,000
-4,600
-23% -$33.2K ﹤0.01% 8523
2018
Q2 		$146K Sell
19,600
-8,900
-31% -$70K ﹤0.01% 8084
2018
Q1 		$245K Buy
28,500
+3,400
+14% +$28K ﹤0.01% 7039
2017
Q4 		$198K Buy
+25,100
New +$188K ﹤0.01% 7127
2017
Q3 		– Sell
-11,800
Closed -$80K – 8605
2017
Q2 		$80K Buy
+11,800
New +$64.7K ﹤0.01% 6979
2015
Q2 		– Sell
-400
Closed -$2K – 9557
2015
Q1 		$2K Sell
400
-1,500
-79% -$7.39K ﹤0.01% 8448
2014
Q4 		$10K Buy
1,900
+100
+6% +$510 ﹤0.01% 8151
2014
Q3 		$9K Sell
1,800
-1,400
-44% -$7.52K ﹤0.01% 7797
2014
Q2 		$18K Buy
3,200
+100
+3% +$607 ﹤0.01% 7370
2014
Q1 		$22K Buy
3,100
+200
+7% +$1.32K ﹤0.01% 7263
2013
Q4 		$18K Sell
2,900
-100
-3% -$603 ﹤0.01% 6547
2013
Q3 		$18K Sell
3,000
-300
-9% -$1.43K ﹤0.01% 6299
2013
Q2 		$13K Buy
+3,300
New +$12.3K ﹤0.01% 6188

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's SVA Position: Q4 2017 in Review

Citadel Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q4 2017, closing a stake of 34,193 shares — an estimated $256K sold.

Citadel Advisors first reported a position in SVA in Q2 2013 and held it in 10 quarters. The position peaked at $958K in Q2 2014. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.

  • Citadel Advisors reported no remaining Sinovac Biotech, Ltd position as of Q4 2017 after selling out during the quarter.
  • Citadel Advisors sold 34,193 Sinovac Biotech, Ltd shares in Q4 2017, an estimated $256K.
  • Citadel Advisors first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 10 quarters.
  • Citadel Advisors's Sinovac Biotech, Ltd position peaked at $958K in Q2 2014.
  • 31 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2017.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.